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a  b  s  t  r  a  c  t
Background: Albuminuria was widely considered as the ﬁrst clinical sign of diabetic kidney
disease (DKD), which is why it has traditionally been used as a screening test for DKD. How-
ever, increasing evidence has shown that a signiﬁcant number of type 2 diabetes mellitus
(DM) patients have a decreased glomerular ﬁltration rate (GFR) without signiﬁcant albumin-
uria,  known as non-albuminuric DKD (NA-DKD). The aim of this study was to determine the
prevalence and the demographic and clinical characteristics of patients with NA-DKD.
Methods: This was a 1-year retrospective study that included 146 type 2 diabetic patients with
GFR < 75 mL/min followed-up in a diabetes outpatient department. Patients were divided
into  two groups according to their ACR status – NA-DKD and albuminuric DKD (A-DKD).
Results: Of the 146 patients included in the study, 53.4% had A-DKD and 46.6% had NA-DKD.
According to the multivariable analysis performed, patients with NA-DKD tended to be older
(p  = 0.021), female (p = 0.045) and with a lower GFR (p = 0.004) than A-DKD patients.
There was no difference between the groups in terms of body mass index, metabolic
control of DM, duration of DM diagnosis and prevalence of metabolic syndrome.
Conclusions: The majority of patients with DKD had albuminuria, but a signiﬁcant proportion
had  a non-albuminuric phenotype (46.6% in this population). These patients exhibit distinct
clinical features that could have screening, therapeutic and prognosis implications.© 2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is anopen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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211-6995/© 2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Enfermedad  renal  diabética:  ¿hay  un  fenotipo  de  no  albuminuria





r  e  s  u  m  e  n
Introducción: La albuminuria fue ampliamente considerada como el primer signo clínico de
la  enfermedad renal diabética (DKD), por lo que se ha utilizado tradicionalmente como
prueba de detección para DKD. Sin embargo, el aumento de la evidencia ha demostrado que
un número importante de pacientes con diabetes mellitus tipo 2 (DM) tenían disminución de
la  ﬁltración glomerular (TFG), sin albuminuria signiﬁcativa (DKD sin albuminuria (NA-DKD).
El  objetivo de este estudio fue determinar la prevalencia y las características demográﬁcas
y  clínicas de los pacientes con NA-DKD.
Métodos: Este fue un estudio retrospectivo de un an˜o que incluyó a 146 diabéticos tipo 2 con
TFG  < 75 ml/min seguidos en el departamento de diabetes. Los pacientes fueron divididos
en  2 grupos de acuerdo a su estado de ACR NA-DKD y DKD albuminúrica (A-DKD).
Resultados: De los 146 pacientes incluidos en el estudio, 53,4% tienen A-DKD y 46,6% tienen
a  NA-DKD. En comparación con los pacientes con A-DKD, aquellos con NA-DKD eran más
propensos a ser de mayor edad (p = 0,021), a ser mujeres (p = 0,045) y tenían una TFG menor
(p  = 0,004), datos conﬁrmados en el análisis multivariante.
El  índice de masa corporal, el control metabólico de la DM, la duración del diagnóstico de
DM  y la prevalencia de síndrome metabólico no fueron diferentes entre los grupos.
Conclusiones: La mayoría de los pacientes con DKD presentan albuminuria, pero una pro-
porción signiﬁcativa tiene un fenotipo de no albuminuria (46,6% en esta población). Estos
pacientes presentan características clínicas diferentes, lo que podría tener relevancia en la
proyección, el pronóstico o implicaciones terapéuticas.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/Introduction
Diabetes mellitus (DM) is the leading cause of chronic kidney
disease (CKD) and end stage renal disease (ESRD) in developed
countries.1 In diabetic patients, early detection of diabetic kid-
ney disease (DKD) is of critical importance.
Albuminuria was widely accepted as the earliest marker of
DKD progression and was traditionally used as a screening test
for DKD.1 Since 1980s, renal disease in diabetes has been clas-
siﬁed in stages deﬁned by increased albuminuria/proteinuria
levels (normo-micro-macro). Classically, the development of
macroalbuminuria or overt proteinuria marked the initiation
of faster glomerular ﬁltration ratio (GFR) declining.2
However, several studies have criticized this deﬁnition in
the last decades. They described progressive declining of GFR
without signiﬁcant albuminuria in subjects with type 1 or type
2 diabetes, i.e. a non-albuminuric DKD (NA-DKD).3,4 Although
declining GFR can occur without albuminuria, the develop-
ment of advanced CKD stages seems to be strongly dependent
on the progression to albuminuria greater than 300 mg/dL.5
The majority of the studies found that the rising in albu-
minuria is accompanied by GFR decline.3–5 These ﬁndings
suggested that decreased GFR could be, for some group of
diabetics, an early marker of DKD.
In the last few years, the traditional concept of the natural
history of DKD has changed. This evidence has led the Amer-
ican Diabetes Association (ADA) to recommend the screening
of DKD based on the albumin excretion ratio (AER) and esti-
mated GFR (eGFR).2by-nc-nd/4.0/).
In addition, albuminuria as a marker of glomerular lesion
progression has some limitations because of its intra-patient
variability and possibility of spontaneous regression (in over
50% of patients with lower levels of albuminuria),6 in contrast
with GFR that has low variability and infrequent improvement.
Growing evidence has shown that there is a continuous
relationship between the level of albuminuria and the decline
of GFR and cardiovascular (CV) risk. It should be noted that
the levels of urinary AER, even within normal ranges, are pos-
itively correlated with the declining of GFR and cardiovascular
risk.7–10
The prevalence and which patients develop NA-DKD are
not completely deﬁned.
The aim of this study was to evaluate the prevalence and
the demographic and clinical characteristics of type 2 diabetic
patients with NA-DKD.
Subjects  and  methods
Study  design
This was an observational, 1-year retrospective, single-centre
study of a cohort of type 2 diabetic patients followed in an
outpatient department.
PopulationFrom the 731 patients followed in a diabetes outpatient
department of our Hospital between 09/2012 and 09/2013, 457
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- Acti ve ur inary
sedimen t 
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ACR ≥ 30 ACR < 30
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Fig. 1 – Flow-chart of study. (DM Diabetes mellitus; CKD
Chronic Kidney Disease; GFR Glomerular ﬁltration rate; ACR






































Table 1 – Clinical and biochemical parameters of the
studied population.
Variable Patients (n = 146)
Age, years 73.1 (9.5)
Male gender 84.0 (57.5%)
Duration of diabetes, years, median 16.0 (11-27)
Hypertension 116.0 (79.5%)
Body mass index, kg/m2 28.5 (5.0)
Metabolic syndrome 77.0 (52.7%)
Haemoglobin, g/dL 12.4 (1.6)
Glicated haemoglobin, % 6.9 (1.1)
GFR, mL/min 50.4 (15.6)
Albuminuria, mg/g 189.4 (477.8)
Coronary heart disease 48.0 (32.9%)
Cerebrovascular disease 10.0 (6.8%)
Diabetic neuropathy, % 25.0 (17.1%)
Peripheral artery disease, % 14.0 (9.6%)
Diabetic retinopathy, % 23.0 (15.8%)
Insulin 61.0 (41.8%)
Renin-angiotensin system inhibitors 101.0 (69.2%)iabetic Kidney Disease (DKD); NA-DKD Non-albuminuric
KD).
atients were haphazardly selected. Inclusion criteria for this
tudy were type 2 DM,  age greater than 18 years old and the
atient had to be followed at the outpatient department for at
east 3 months.
From the 457 diabetic patients evaluated, patients with
ype 1 diabetes (n = 20), secondary diabetes (n = 25), other
robable causes for CKD (n = 17), need for renal replacement
herapy (n = 6) and insufﬁcient information in the clinical pro-
ess (n = 48) were excluded from the analysis. In order to
xclude other probable causes for kidney disease all patients
ith an active urinary sediment and nephrotic proteinuria
n = 7), were excluded (Fig. 1). In order to standardize the pop-
lation, patients with eGFR higher than or equal to 75 mL/min
n = 188) were also excluded from the analysis.
After the application of these exclusion criteria,
46 patients remained in the study. eGFR was determined
sing the standard Chronic Kidney Disease Epidemiology
ollaboration formula (CKD-EPI). The spot urine albu-
in/creatinine ratio (ACR) was used to determine the
lbuminuria range, and we  considered albuminuria when
CR was greater than or equal to 30 mg/g. According to this
eﬁnition, the patients with eGFR < 75 mL/min, were divided
n two groups: NA-DKD – patients without albuminuria and
lbuminuric DKD (A-DKD) – patients with albuminuria (Fig. 1).
In NA-DKD patients the results of all previous ACR mea-
urements available at clinical process were reviewed and
atients that had albuminuria before the renin-angiotensin
ystem (RAS) inhibitor use were excluded, to eliminate any
atient whose normoalbuminuric status was related to RAS
nhibitor use.
Information concerning demograﬁc data, including age,
ender, date of diabetes diagnosis, use of antidiabetic and
ypotensive medications was collected from the clinical pro-
ess. Details of physical examination such as weight, height
for body mass index calculation – BMI) and blood pres-
ure, and also results from the most recent blood tests
nd laboratory urinalysis were also assessed by clinical
rocess analysis. Presence or absence of past history of dia-
etic retinopathy (diagnosed by fundoscopy) and neuropathy,Values are: mean (SD), median (interquartile range) or frequencies
[n(%)].
arterial hypertension (systolic blood pressure >140 mmHg
and/or diastolic blood pressure >90 mmHg), coronary heart
disease, cerebrovascular disease and peripheral vascular dis-
ease (diagnosed by Doppler ultrasound) was also recorded.
Metabolic syndrome was deﬁned according to the deﬁnition
published by World Health Organization (WHO).
Statistical  analysis
Variables are expressed as frequencies for categorical vari-
ables, mean values with SD for continuous variables and
median values with interquartile ranges for ordinal variables.
Comparison between groups was performed using T-test
for normally distributed variables, Wilcoxon test for non-
normally distributed variables and 2 test for categorical
variables. Spearman correlation was also used for univariable
analyis.
Logistic regression analysis was used for multivariable
analysis.
Statistical analysis was performed with SPSS system 21.0
(SPSS Inc., Chicago, IL). For all comparisons, a p < 0.05 was con-
sidered statistically signiﬁcant.
Results
Of the studied population (n = 146), 57.5% were male; mean
age was 73.1 ± 9.5 years and with a median time of diabetes
diagnosis of 16 years. Mean glicated haemoglobin (HbA1c) was
6.9 ± 1.1% and 26.9% were treated with insulin. Mean GFR
was 50.4 ± 15.6 mL/min, mean albuminuria was 189.4 ±
477.8 mg/g and mean haemoglobin was 12.4 ± 1.6 g/dL.
Almost 80% of the patients had hypertension, 32.9% had
coronary heart disease, 6.8% had cerebrovascular disease,
15.8% had diabetic retinopathy and 9.6% had peripheral artery
disease (Table 1).
Of the 146 patients with eGFR < 75 mL/min, 78 (53.4%) had
also albuminuria (A-DKD group) and the remaining 68 patients
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Table 2 – Clinical and laboratorial characteristics of patients with diabetic kidney disease.
NA-DKD (n = 68) A-DKD (n = 78) p
Age, years 75.1 (8.5) 71.0 (10.2) 0.021
Male gender, % 48.5 65.4 0.045
Duration of diabetes, years, median 19.0  (10-30) 16.0 (11-25) ns
More than 15 years of diabetes, % 38.2 44.9 ns
Dyslipidemia, % 52.9 67.9 ns
Hypertension, % 66.2 91.0 0.000
Body mass index, kg/m2 29.4 (5.5) 27.6 (5.2) ns
Body mass index higher than 25 kg/m2, % 47.1 56.4 ns
Metabolic syndrome, % 50.0 55.1 ns
Haemoglobin, g/dl 11.8 (1.5) 12.5 (1.7) 0.020
Glicated haemoglobin, % 6.7 (0.8) 7.0 (0.8) ns
Total cholesterol, mg/dL 148.7 (28.0) 162.2 (47.0) ns
Triglycerides, mg/dL 127.7 (54.5) 140.9 (60.2) ns
HDL, mg/dL 47.8 (16.3) 48.7 (15.9) ns
LDL, mg/dL 75.5 (19.9) 85.6 (39.2) ns
Uric Acid, mg/dL 5.8 (1.4) 6.2 (1.3) 0.044
GFR, mL/min 45.8 (14.9) 48.8 (14.4) 0.004
Albuminuria 10.9 (7.8) 202.6 (271.0) 0.000
Systolic pressure, mmHg 131.1 (15.0) 133.9  (14.6) ns
Diastolic pressure, mmHg 68.1 (10.2) 73.2  (11.3) ns
Pulse pressure, mmHg 62.4  (17.2) 62.3 (13.9) ns
GFR, glomerular ﬁltration rate; NA-DKD, non-albuminuric diabetic kidney disease; A-DKD, albuminuric diabetic kidney disease; ns, not signiﬁ-
(%)].
GFR (OR 0.95, 95% CI 0.93–0.97, p < 0.001) but not with hyperten-
sion and CAD. This model was statically signiﬁcant (p < 0.001),cant.
Values are: mean ± SD, median (interquartile range) or frequencies [n
(46.6%) had only decreased eGFR, without albuminuria (NA-
DKD group).
The albuminuric phenotype was more  frequent in males
(65.4%) and the non-albuminuric phenotype was slightly more
prevalent in females (51.5%) (p = 0.045).
Compared with patients with albuminuria, those with-
out albuminuria were more  likely to be older (75.1 vs. 71.0
years, p = 0.021). The duration of diabetes diagnosis was simi-
lar between groups.
NA-DKD patients also had a lower eGFR (45.8 vs.
48.8 mL/min, p = 0.004) and lower haemoglobin concentration
(11.8 vs. 12.5 g/dL, p = 0.020) (Table 2).
NA-DKD group had lower hypertension prevalence than A-
DKD (66.2 vs. 91.0%, p < 0.001), and in concordance with this
was under fewer hypotensive drugs (median of 1 vs. 2 hypoten-
sive drugs, p < 0.001) and was less frequently medicated with
RAS inhibitors (58.8 vs. 78.2%, p = 0.013) (Tables 3 and 4). Nev-
ertheless, the mean diastolic and systolic blood pressures
measured in ofﬁce were similar between groups.
Patients with non-albuminuric phenotype took fewer oral
antidiabetics (median of 1 vs. 2 oral antidiabetics, p = 0.001)
Table 3 – Distribution of target-organ damage of the
patients with DKD.
NA-DKD A-DKD p
Coronary heart disease (%) 22.0 42.3 0.013
Cerebrovascular disease (%) 7.4 6.4 ns
Diabetic neuropathy (%) 17.6 16.7 ns
Peripheral artery disease (%) 13.2 6.4 ns
Diabetic retinopathy (%) 11.8 19.2 ns
NA-DKD, non-albuminuric diabetic kidney disease; A-DKD, albu-
minuric diabetic kidney disease; ns, not signiﬁcant.and were less frequently treated with insulin (30.9 vs. 51.3%,
p = 0.013), however the metabolic control of diabetes (evalu-
ated by HbA1c) was similar between groups (Tables 3 and 4).
Prevalence of metabolic syndrome was also similar in the two
groups.
Patients with non-albuminuric phenotype had signiﬁcantly
lower prevalence of coronary heart disease (22.1 vs. 42.3,
p = 0.013), while the prevalence of the other diabetes target-
organ damage like retinopathy, neuropathy, cerebrovascular
disease and peripheral artery disease was not different
between groups (Table 3).
The multivariable analysis (logistic regression), adjusted to
gender, age, GFR, hypertension and CAD prevalence, showed
that developing NA-DKD was positively associated with age
(OR 1.07, 95% CI 1.02–1.11, p = 0.005) and female gender (OR
3.11, 95% CI 1.35–7.17, p = 0.008) and negatively associated withhowever it only explains 32% (R2 = 0.32) of NA-DKD prevalence.
Table 4 – Anti-diabetic and hypotensive medication
in diabetic kidney disease patients.
NA-DKD A-DKD p
Number of oral antidiabetics
(median)
1.0  (1-2) 2.0 (0-3) 0.001
Insulin (%) 30.9 51.3 0.018
Number of hypotensive drugs
(median)
1.0 (0-2) 2.0 (1-3) 0.000
Renin-angiotensin system
inhibitors (%)
58.8  78.2 0.013
NA-DKD, non-albuminuric diabetic kidney disease; A-DKD, albu-
minuric diabetic kidney disease.
















































wn e f r o l o g i a 2 0 1
Spearman’s correlation was run to determine the relation-
hip between GFR and albuminuria. There was a negative
orrelation between these two variables (rs = −0.166, p = 0.036).
iscussion
lbuminuria has been used classically as the ﬁrst sign of renal
nvolvement in diabetic patients and it is also used to evalu-
te the progression of DKD.1,2 However, in the last few years
rowing evidence has shown that a signiﬁcant proportion of
iabetic patients has decreased GFR without albuminuria, the
o called NA-DKD.3,4
In our patients approximately one half (46.6%) of all
atients with DKD had just decreased GFR without albumin-
ria, which is in accordance with other authors that found a
revalence of 13–69.4% of NA-DKD.3,11–15
Using albuminuria as an early marker of DKD onset
r progression requires a careful interpretation because
n diabetic patients albuminuria has a great tendency to
egress spontaneously to normal levels. Some authors4,16
ound that approximately 18–51% of type 2 diabetic patients
followed during 2–10 years) initially albuminurics became
on-albuminurics spontaneously during follow-up time. On
he other hand, United Kingdom Prospective Diabetes Study
UKPDS)17 showed that some diabetic patients pass directly
rom a normoalbuminuric stage to renal insufﬁciency (0.1%
er year).
Although, some authors, such as Pavkov and colleagues5,
dvocated that in DKD the declining of GFR may precede the
nset of albuminuria, they still defend that the progression to
KD stage 5D is strongly dependent on the appearance of albu-
inuria (especially albuminuria greater than 300 mg/g). This
nding is in accordance with our results of a signiﬁcant nega-
ive correlation between albuminuria and decreased eGFR.
Given the large intra-patients albuminuria variability and
he possibility of bypassing the classic stages of the natu-
al history of diabetic nephropathy, trusting albuminuria to
dentify and evaluate the progression of DKD may delay the
iagnosis of a signiﬁcant proportion of patients. A new con-
ept for the natural history of diabetic nephropathy assumes
lbuminuria and decreased GFR as complementary mani-
estations of DKD, but not obligatory or temporarily related
anifestations.4,5,18
In comparison to albuminuria, GFR has some advantages
s a marker of renal impairment: spontaneous regression is
nlikely and it’s reduction is usually progressive.
Non-albuminuric patients were older and were 3 times
ore  frequently female, which is in accordance with other
uthors.12,19 Although, there is a nephron loosing related to
ge, older ages have been related not only with lower GFR but
lso with higher albuminuria.17,25
The female tendency for NA-DKD is a consistent ﬁnding in
ther studies,12,19 but the reasons for this association are still
nknown.20 NDR25 and UKPDS17 studies in diabetic patients
uggested that female gender is a risk factor for renal impair-
ent (GFR ≤ 60 mL/min), while male gender is associated with
he development of albuminuria.
It contrasts with the known faster decline of GFR in males
ith kidney diseases other than DKD, and male gender has(5):503–509 507
been proposed as a protective factor in the development of
reduced GFR in diabetic patients.17,20
Penno and colleagues21 showed that the majority of
patients with type 2 DM with diabetic retinopathy and
DKD had increased albuminuria (independently of decreased
eGFR), which reinforces that retinopathy is a risk marker for
albuminuria but not for decreased eGFR. According to our
results, we found that NA-DKD patients had more  advanced
CKD with lower eGFR and lower haemoglobin. This association
suggests that NA-DKD patients have histologic lesions closer
to macroangiopathy and interstitial disease with reduced
renal mass, than a glomerulopathy alone. Some authors22
demonstrated that diabetic patients with decreased eGFR had
a higher intrarenal resistive index, and that there was no asso-
ciation between albuminuria range and this index, suggesting
a role for intrarenal vascular disease in renal insufﬁciency in
NA-DKD patients. Many authors have also assumed choles-
terol emboli as a frequent cause of decreased GFR in diabetic
patients.23
We  also found that metabolic syndrome prevalence was not
different between albuminuric and non-albuminuric patients,
however we noted a tendency to higher prevalence of some
metabolic syndrome criteria, such as hypertension, dyslipi-
daemia and hypertriglyceridaemia, in albuminuric group.
Nevertheless, the only study we  found that analyzed the
prevalence of this syndrome in NA-DKD,14 found it more
frequent in non-albuminuric patients. Other studies,20,24,25
although not directed to the prevalence of metabolic
syndrome, found contradictory results in respect to the preva-
lence of isolated metabolic syndrome traits.
It is unclear why some patients develop DKD with signiﬁ-
cant albuminuria, while others have impaired renal function
associated with very low levels of albuminuria. Evidently,
diabetic patients can develop renal disease other than dia-
betic nephropathy, as occurs in any individual, therefore a
superimposed non-diabetic kidney disease could explain this
phenotype. Some authors26 showed that more  than 95% of
renal diseases in type 1 diabetic patients were result of a dia-
betic glomerulosclerosis, unlike in type 2, which is a more
heterogeneous group. Twelve to eighty-one percent of renal
biopsies of type 2 diabetes patients presented a renal disease
unrelated to diabetes.26,27 However, we must be aware of the
selection criteria in these studies for doing renal biopsy in
type 2 diabetes patients with renal injury – most of them had
nephrotic proteinuria or hematuria, which suggests a super-
imposed non-DKD.
A frequent question is, if the development of NA-DKD can
be due to hypertensive nephroangiosclerosis, the second main
cause of CKD in developed countries and a frequent comor-
bidity in type 2 diabetic patients (79.5% of our diabetics had
hypertension). However, in our study, hypertension prevalence
was similar between groups and albuminuric patients took
more hypotensive drugs and more  renin-angiotensin system
inhibitors making nephroangiosclerosis an unlikely cause for
decreased GFR in NA-DKD group.
It has been also suggested that RAS inhibitors can mask
albuminuria and can justify the non-albuminuric phenotype.
Nevertheless, in our study we excluded any patient whose
normo-albuminuric status was related to RAS inhibitor ini-
tiation.
 0 1 6;
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In our patients the metabolic control of diabetes (evaluated
by HbA1c) was not different between albuminuric and non-
albuminuric patients. However, the UKPDS study17 shown that
HbA1c is predictor for albuminuria, but not for decreased GFR
in diabetic patients.
NEFRON 11 study28 found unexpectedly a similar frequency
of nonalbuminuric renal impairment between general popu-
lation and diabetic patients. These authors suggest that it is
possible that NA-DKD is being increasingly identiﬁed due to
the current recommendations of screening DKD by calculating
GFR and measuring albuminuria.
Budhiraja et al.29 evaluated 10 biopsy specimen’s obtained
from type 2 diabetic patients who  underwent nephrectomy
for renal cancer and had decreased GFR without proteinuria
and found changes consistent with diabetic glomerulosclero-
sis. They assumed that the absence of proteinuria in presence
of advanced glomerular lesion could be due to reabsorption of
proteinuria by relatively preserved tubules.
An Israeli work group30 performed a study in rats (experi-
mental models of type 2 diabetes) and found strong evidence
that NA-DKD occurred with histopathology ﬁndings con-
sistent with diabetic nephropathy, suggesting that NA-DKD
phenotype was really diabetic nephropathy and no other
cause. They suggested that the development of one phe-
notype instead of another might be explained by genetic
determinants. However, a recent biopsy study31 of 31 type
2 diabetic patients with decreased eGFR, explored the renal
structural changes in albuminuric (n = 23) and normoalbumin-
uric (n = 8) patients, and found more  heterogeneity of the renal
lesions in non-albuminuric than in albuminuric subjects. They
found that in non-albuminuric subjects just half had typical
glomerulopathy (present in almost all A-DKD patients), fre-
quent predominantly interstitial or vascular changes and the
majority of them had some degree of arteriosclerosis. These
results suggest the implication of diverse pathogenic factors
such as age, blood pressure and intrarenal vascular disease.
Caromoni and colleagues32 evaluated 23 renal biopsies of
patients with type 1 diabetics who  had NA-DKD and also
found glomerular changes consistent with a typical diabetic
nephropathy. The scarce studies comparing renal biopsy ﬁnd-
ings in NA-DKD and A-DKD patients does not enable us to
identify which histopathologic mechanism is behind of the
non albuminuric phenotype.
Porrini et al.20 showed that NA-DKD patients had a rate of
GFR decline of 3.5 mL/min/1.73 m2 (which means a 2–5 times
faster decline than in the healthy population) and that A-DKD
patients had an even higher decline of GFR. Perkins et al.33
found that also in type 1 diabetic patients the decline rate
of eGFR was higher in albuminuric than in non-albuminuric
subjects.
Rigalleau11 and Zeeuw34 found that NA-DKD patients had a
lower risk of progression to CKD stage 5D (lower decline in GFR
and lower increase in albuminuria). Remuzzi and Bertani35
postulated that albuminuria is not only a marker of severity of
kidney disease but also albuminuria itself could damage the
kidney.
Patients with NA-DKD presented lower all-cause mortal-
ity in several studies11,36 in comparison with albuminuric
patients, suggesting that NA-DKD may have a better prognosis
than A-DKD.3  6(5):503–509
RIACE Study Group37 found a lower rate of cardiovascu-
lar events in NA-DKD, what could probably be, even partially,
related to the fact that albuminuria is a cardiovascular risk
marker.
The main limitation of our study, like the majority of NA-
DKD studies, was the impossibility to conﬁrm histologically
with renal biopsy specimens if NA-DKD patients had glomeru-
lar lesions consistent with diabetic nephropathy or another
cause for decreased GFR. Some questions still remain unan-
swered: why some patients develop NA-DKD; if the traditional
medical approach used to prevent or delay the progression of
DKD has the same efﬁcacy in NA-DKD patients and if NA-DKD
is a different phenotype of DKD or just an alternative pathway
of DKD.
Conclusions
Early decreased GFR without albuminuria is increasingly rec-
ognized as a marker of DKD in a signiﬁcant proportion of
diabetic patients (46.6% in our study). Patients with NA-DKD
seem to exhibit distinct clinical features from A-DKD, which
could have therapeutic, screening and prognosis implications.
The existence of these new phenotype or pathway in diabetic
nephropathy suggests the necessity to review our understand-
ing and classiﬁcation of diabetic nephropathy as a 5 stage
progressive process. However, albuminuria still has a strong
prognostic importance and it is an important cardiovascular
risk marker.
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